Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
REGENXBIO Inc.
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD). Information collected in this study may be used to identify potential participants for DMD investigational gene therapy clinical trials.
This study consists of:
* A phone/video interview or at an in-clinic visit to provide e-consent and medical history
* A single home health visit or subsequent in-clinic visit to collect blood sample for antibody testing
* A phone/video call for communication of AAV8 antibody test results
Age
0–25
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Males at least 0 to \<25 years of age
Diagnosis of DMD
Provision of signed and dated informed consent form (ICF) and assent as required per local regulations or requirements
You may not be if
Prior participation in a gene therapy trial OR recipient of a gene therapy drug